Conclusion: the complaint was confirmed.The affinity nt cardiotomy venous reservoir (cvr) was returned, and visual inspection showed no outward signs of physical damage or abnormalities.The device appears to have been used.The affinity nt cvr was cleaned using a renalin solution.Performance analysis was performed and there appeared to be no resistance of flow through the filter screen.The device performance was as expected, and analysis could not duplicate the reported event.The required cleaning of the returned device could have cleared any biomaterial from the filter.Blood residue within the device can prevent performance testing as travel time for returned devices causes the residue to clot and dry on the device.Cleaning the device reduces biohazard for employees and returns the device to a 'pre-use' like state.A video was provided that confirmed the reported event.The root cause is unknown, but this type of event is typically associated with protein build up / clotting.Although it may have been momentary, an event that enables clotting can affect the filter performance even if the majority of the case maintained an acceptable anticoagulation protocol.The ifu for the affinity nt cvr states the following: a strict anticoagulation protocol should be followed, and anticoagulation should be routinely monitored during all procedures.The benefits of extracorporeal support must be weighed against the risk of systemic anticoagulation and must be assessed by the prescribing physician.Adequate heparinization must be maintained before and during bypass.Trends for issues with this device are monitored.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|